Vinorelbine and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Vinorelbine (vinorelbine), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Lapatinib, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Nosebleed when taking Vinorelbine. It is created by eHealthMe based on reports of 6,375 people who have side effects when taking Vinorelbine from the FDA, and is updated regularly.

What is Vinorelbine?

Vinorelbine has active ingredients of vinorelbine. eHealthMe is studying from 6,381 Vinorelbine users. Check the latest studies of Vinorelbine.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,082 drugs and 3,091 conditions by eHealthMe. Check the latest studies of Nosebleed.

On May, 13, 2026

6,375 people reported to have side effects when taking Vinorelbine.
Among them, 68 people (1.07%) have Nosebleed.

Among these 68 people:

How long have people been on Vinorelbine when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Vinorelbine? *

female: 98.33 %
male: 1.67 %

What is the age of people who have Nosebleed when taking Vinorelbine? *

What are other drugs people take besides Vinorelbine? *

What are other side effects people have besides Nosebleed? *

Headache (pain in head): 43 people, 63.24%
Nausea (feeling of having an urge to vomit): 40 people, 58.82%
Cough: 39 people, 57.35%
Nausea And Vomiting: 24 people, 35.29%
Pain In Extremity: 22 people, 32.35%
Muscle Aches (muscle pain): 21 people, 30.88%
Chest Pain: 20 people, 29.41%
Bone Pain: 20 people, 29.41%
Neuropathy Peripheral (surface nerve damage): 20 people, 29.41%
Chills (felling of cold): 20 people, 29.41%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 35 people, 51.47%
Dyspnea (difficult or laboured breathing): 20 people, 29.41%
Hepatic Pain (pain in liver): 19 people, 27.94%
Back Pain: 19 people, 27.94%
Respiratory Tract Infection: 19 people, 27.94%
Pulmonary Embolism (blockage of the main artery of the lung): 19 people, 27.94%
Vitamin D Decreased: 16 people, 23.53%
Blood Calcium Decreased: 16 people, 23.53%
Bone Pain: 16 people, 23.53%
Itching: 10 people, 14.71%

* Approximation only. Some reports may have incomplete information.

Do you take Vinorelbine and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vinorelbine:

Vinorelbine (6,381 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Vinorelbine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,082 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,091 conditions)

Related publications that referenced our studies

Mohammad MM, Syrigos KN, Saif MW, "Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma", Case reports in dermatological medicine, 2013 Sep .
Mohammad MM, Syrigos KN, Saif MW, "Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma", Case reports in dermatological medicine, 2013 Sep .

How the study uses the data?

The study uses data from the FDA. It is based on vinorelbine (the active ingredients of Vinorelbine) and Vinorelbine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.